(lp0
S"How VIVUS Inc  Delivered A Better ROE Than Its Industry? Simply Wall St - Mar 8, 2017 Over the past 12 months, VIVUS Inc  generated an ROE of 273.4%, implying the company created 273.4 cents on every dollar of shareholders' invested capital.VIVUS, Inc.  Scheduled to Post Earnings on Wednesday - BNB Daily VIVUS, Inc.  moves down at least -0.27% on its earnings reaction day - Post Analyst"
p1
aS"Thursday's Market Insights: Apricus Biosciences Inc , VIVUS, Inc. (VVUS ... Smarter Analyst - Mar 9, 2017 Apricus Biosciences Inc  shares are rising by 3% in Thursday's trading on the news that Apricus has completed the sale to Ferring International of its topical cream Vitaros.VIVUS  Posts Strong Profit Growth; Apricus Biosciences  Soars on ... - Galaxy Stocks  After-Hours Movers 03/08:    Higher;   (WATT ... - StreetInsider.com"
p2
aS"VIVUS  Beats on Q4 Earnings, Revenues Increase Y/Y Zacks.com - Mar 9, 2017 VIVUS Inc.  reported earnings of 54 cents per share in the fourth quarter of 2016 as against a loss of 12 cents in the year-ago period.VIVUS, Inc.  Efforts To Reshape VIVUS' Business Model - StockNewsUnion"
p3
aS'Decision Time: VIVUS Inc  Stock Technicals Have Hit an Inflection ... CML News - 22 hours ago Decision Time: VIVUS Inc  now sits in the perhaps the most difficult technical position -- the stock has no urgency in its direction and that has left it at an inflection point.'
p4
aS'Vivus Inks Deal For Stendra - Why Street Reaction Is Muted Seeking Alpha - Oct 4, 2016 Vivus  announced today that it has reached a deal withy Metuchen Pharmaceuticals for the rights to the erectile dysfunction drug Stendra in the United States, Canada, South America, and India.VIVUS and Metuchen Pharmaceuticals Announce License Agreement for Commercial ... - Marketwired VIVUS Licenses Stendra Rights to Metuchen Pharmaceuticals - Nasdaq'
p5
aS'Vivus: A Speculative Play Just Got A Little More Speculative Seeking Alpha - Jun 22, 2016 Vivus  investors got yet another round of bad news today when the company filed an 8K with the SEC announcing that Hetero USA has filed an ANDA with the FDA to make generic versions of all Stendra doses.'
p6
aS"VIVUS, Inc.  Shares Down 0% Following Insider Selling Chaffey Breeze - Mar 15, 2017 VIVUS logo VIVUS, Inc. 's share price was down 0% during trading on Monday after an insider sold shares in the company.The North Tide Capital, Llc Sells 1149400 Shares of VIVUS, Inc.  Stock - Petro Global News 24Insider Selling: VIVUS, Inc.  Major Shareholder Sells $1333304.00 in Stock - Sports Perspectives"
p7
aS'Stock Returns: AcelRx Pharmaceuticals Inc  versus VIVUS Inc ... CML News - Mar 16, 2017 This is a snapshot to compare the stock returns for AcelRx Pharmaceuticals Inc  versus VIVUS Inc  .'
p8
aS"Traders Secrets on VIVUS, Inc. , McDermott International, Inc.  StockNewsJournal - Mar 10, 2017 Investors who are keeping close eye on the stock of VIVUS, Inc.  established that the company was able to keep return on investment at -21.11 in the trailing twelve month while Reuters data showed that industry's average stands at 13.50&nbsp;..."
p9
aS"Vivus: Qsymia Sales Trudge Along - Investors Need Growth, Not Flatness Seeking Alpha - Jun 6, 2016 Some Vivus  investors seem to be in that boat. They are even celebrating the fact that Vivus' Qsymia did not do as bad as another player in the space last week despite the fact that Qsymia sales are still much lower than they need to be ..."
p10
a.